Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study Mao-Song Tsai, Sui-Yuan Chang, Shu-Wen Lin, Ching-Hua Kuo, Hsin-Yun Sun, Bin-Ru Wu, Sue-Yo Tang, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung, Shan-Chwen Chang Journal of Microbiology, Immunology and Infection Volume 50, Issue 6, Pages 789-797 (December 2017) DOI: 10.1016/j.jmii.2015.12.012 Copyright © 2016 Terms and Conditions
Figure 1 Time-to-virological failure in patients who switched to unboosted atazanavir plus two nucleos(t)ide reverse-transcriptase inhibitors (tenofovir-based vs. non-tenofovir-based regimens). TDF = tenofovir disoproxil fumarate. Journal of Microbiology, Immunology and Infection 2017 50, 789-797DOI: (10.1016/j.jmii.2015.12.012) Copyright © 2016 Terms and Conditions
Figure 2 Plasma atazanavir concentrations, tenofovir/lamivudine + unboosted atazanavir, and abacavir-lamivudine (or zidovudine-lamivudine) + unboosted atazanavir. Journal of Microbiology, Immunology and Infection 2017 50, 789-797DOI: (10.1016/j.jmii.2015.12.012) Copyright © 2016 Terms and Conditions
Figure 3 Forest plot showing the risk of virological failure according to subgroups. CI = confidence interval; MDR1 = multidrug resistance 1; PXR = pregnane X receptor. Journal of Microbiology, Immunology and Infection 2017 50, 789-797DOI: (10.1016/j.jmii.2015.12.012) Copyright © 2016 Terms and Conditions